期刊文献+

白血病患者CD33与NPM1和FLT3基因突变相关性分析

Correlation Analysis of CD33,NPM1 and FLT3 Gene Mutations in Leukemia Patients
下载PDF
导出
摘要 目的探讨CD33的量化水平与NPM1和FLT3基因突变的存在或缺失之间的关系。方法选取64例AML患者,使用流式细胞仪对选取的AML患者进行免疫表型分析。结果全部患者白细胞的CD33表达量范围为12%~91%,集中在69%。NPM1突变的病例和不存在突变的病例相比,CD33的MFI和ABC值有显著的差异(P<0.05)。选择27个病例研究CD33的ABC值,显示10个存在NPM1突变病例的ABC值范围为2580~18356,集中在12236,剩余17个没突变的病例的ABC值范围为366~16720,集中在4205(P<0.05)。结论携带NPM1突变的AML患者显示出较高的CD33表达强度,这可为AML的一个更好的相关治疗方案提供思路。
作者 周志刚
机构地区 宜兴市人民医院
出处 《现代诊断与治疗》 CAS 2012年第11期1849-1850,共2页 Modern Diagnosis and Treatment
  • 相关文献

参考文献5

二级参考文献56

  • 1Kelly LM, Gilliland DG. Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet, 2002 ;3 : 179 - 198.
  • 2Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensi- fication in acute myeloid leukemia varies by cytogenetic subgroup. Cancer Res, 1998 ;58 : 4173 -4179.
  • 3Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood, 2002;100:4325 -4336.
  • 4Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood, 1998;92:2322-2333.
  • 5Schlenk RF, Benner A, Hartmann F, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. Leukemia, 2003 ; 17:1521 - 1528.
  • 6Dohner K, Tobis K, Ulrich R, et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol, 2002 ;20 : 3254 - 3261.
  • 7Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults ( 16 to 60 years ) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 2002;100:4372 -4380.
  • 8Frohling S, Schlenk RF, Stolze I, et al. cebpa mutations in younger adults with acute myeloid leukemia and normal cytogenetics : prognostic relevance and analysis of cooperating mutations.J Clin Oncol, 2004 ;22:624 -633.
  • 9Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 2001 ;98 : 1752 - 1759.
  • 10Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of cebpa mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood, 2002 ; 100 : 2717 - 2723.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部